Controlling Symptoms in Patients With MF Treated With Hypomethylating Agents
Srdan Verstovsek, MD, PhD, discusses how to control symptoms while using hypomethylating agents in patients with myelofibrosis.
Srdan Verstovsek, MD, PhD, professor in the Department of Leukemia and director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses how to control symptoms while using hypomethylating agents in patients with myelofibrosis (MF).
The hypomethylating agents are used solely to lower blast and control disease. In some cases, complete responses and partial responses with these agents have been reported, Verstovsek says, but the goal of these agents is to put the disease into a chronic phase with less than 10% blast so that the patient can receive transplant.
According to Verstovsek, the quality of life (QoL) on these agents is not great, while MF in general has many systemic symptoms that cannot be controlled by hypomethylating agents. However, to control the symptoms, the JAK inhibitor ruxolitinib (Jakafi) can be given in combination to help with QoL and the progressive nature of the disease.
Targeted Therapies Continue to Push the Field of EGFRm Lung Cancer Forward
December 6th 2023In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.
Read More
Defining and Treating Classic Cases of Myeloproliferative Neoplasms
November 30th 2023In the first article of a 2-part series, Pankit Vachhani, MD, discusses what makes classical cases of myeloproliferative neoplasms unique and how ruxolitinib impacts their reduction of spleen volume.
Read More
ACVR1 Inhibition With Pacritinib Leads to Anemia Improvement in MF
November 29th 2023Based on in vitro data, pacritinib led to a 4-fold higher potency for inhibition of the hepcidin regulator ACVR1 vs momelotinib among patients with cytopenic myelofibrosis and led to an increase in red blood cell transfusion independence.
Read More
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
Oh Discusses Goals of Treatment in Patients With Cytopenic Myelofibrosis
November 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen T. Oh, MD, PhD, discussed with participants when they would use pacritinib for patients with thrombocytopenia related to myelofibrosis.
Read More
